Zhu Jian-Fang, Wang Chun-Lin
Department of Pediatrics,First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Wang C-L, Email:
Zhongguo Dang Dai Er Ke Za Zhi. 2024 Feb 15;26(2):118-123. doi: 10.7499/j.issn.1008-8830.2309125.
Short stature in puberty significantly affects the physical and mental health of adolescents. The continuous acceleration of skeletal maturation, caused by sex hormones during puberty, limits the time available for growth and poses a considerable challenge for the treatment of short stature. To date, there is still no standardized treatment protocol for this disorder. However, puberty is the last period to improve the final adult height. Currently, commonly used pharmacological treatments in clinical settings include recombinant human growth hormone, gonadotropin-releasing hormone analogs, and third-generation aromatase inhibitors. In recent years, personalized treatment aiming to improve the final adult height has become a key focus in clinical practice. This article provides a comprehensive summary of research on pharmacological therapies for height improvement in pubertal children with short stature, offering valuable insights for healthcare professionals.
青春期身材矮小会显著影响青少年的身心健康。青春期性激素导致骨骼成熟持续加速,限制了生长时间,给身材矮小的治疗带来了巨大挑战。迄今为止,针对这种疾病仍没有标准化的治疗方案。然而,青春期是提高最终成人身高的最后阶段。目前,临床常用的药物治疗包括重组人生长激素、促性腺激素释放激素类似物和第三代芳香化酶抑制剂。近年来,旨在提高最终成人身高的个性化治疗已成为临床实践的关键重点。本文全面总结了青春期身材矮小儿童身高改善药物治疗的研究,为医疗保健专业人员提供了有价值的见解。